SCHEMBL4164050

SCHEMBL4164050

COc1ccc2[nH]c3c(c2c1)CCCC3n1cccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.69
SIRT1 Q96EB6 1/20 0.60
MAPT P10636 4/20 0.53
ALDH1A1 P00352 2/20 0.53
HTR2B P41595 1/20 0.53
MAPKAPK2 P49137 6/20 0.49
HTR1D P28221 1/20 0.49
HTR1B P28222 1/20 0.49
MAPKAPK5 Q8IW41 1/20 0.48
HTR7 P34969 2/20 0.47
CHRM4 P08173 1/20 0.47
DRD2 P14416 1/20 0.47
KDM4E B2RXH2 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
CYP1A2 P05177 3/20 0.44
CYP2D6 P10635 3/20 0.44
ALOX15 P16050 3/20 0.44
RECQL P46063 2/20 0.44
HTR2A P28223 2/20 0.44
HTR2C P28335 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16433425 0.84 DHODH (0.73) DHODHSIRT1ALDH1A1HTR2BKDM4E
SCHEMBL4152072 0.81 DHODH (1.00) DHODHSIRT1MAPTALDH1A1CYP1A2
SCHEMBL4160505 0.81 DHODH (0.73) DHODHSIRT1MAPTALOX15HTR2A
SCHEMBL13925700 0.81 DHODH (0.62) DHODHSIRT1MAPTALDH1A1MAPKAPK2
SCHEMBL21758535 0.80 SIRT1 (0.67) SIRT1MAPTALDH1A1HTR2BMAPKAPK2
SCHEMBL30363189 0.80 MAPKAPK2 (0.56) SIRT1MAPTALDH1A1HTR2BMAPKAPK2
SCHEMBL30363250 0.80 MAPKAPK2 (0.56) SIRT1MAPTALDH1A1HTR2BMAPKAPK2
SCHEMBL4157570 0.79 DHODH (0.70) DHODHSIRT1HTR7CYP2D6MEN1
SCHEMBL31120772 0.79 SIRT1 (0.66) SIRT1MAPTALDH1A1HTR2BMAPKAPK2
SCHEMBL4135119 0.79 SIRT1 (0.66) SIRT1MAPTALDH1A1HTR2BMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control VEGFA, FLT4, KDR DHODH 668/4885SIRT1 680/4885MAPT 2774/4885
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL VEGFA, FLT4, KDR DHODH 668/4885SIRT1 680/4885MAPT 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.